CYP1B1 Gene Glaucoma (Primary Type 3A) Genetic Test – 2,800 AED | DNA Labs UAE

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Sequencing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with a DHA-licensed genetic counselor.
Insurance & Billing: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Turnaround Time: 3–4 weeks with rapid genetic counselling option.

Test Overview & Methodology

The CYP1B1 gene test detects sequence variants causing primary congenital glaucoma type 3A – a severe, early-onset eye disorder. This test empowers families with genetic clarity, enabling early intervention and sight preservation while meeting all UAE genetic screening mandates.

Feature	Our Test (Premium NGS)	Standard Genetic Panels
Precision	Full gene sequencing with CNV detection; 99.9% analytical sensitivity	Targeted genotyping only; limited to common mutations
Methodology	Next‑Generation Sequencing (NGS) confirmed by Sanger sequencing	Microarray or single‑site PCR
TAT	3–4 weeks with rapid genetic counselling option	4–6 weeks; no counselling included

Physician Insight & Safety Protocols

“This test uncovers the genetic blueprint of primary congenital glaucoma; a negative result does not rule out non‑CYP1B1 glaucomas, so comprehensive ophthalmic follow‑up remains essential. We interpret every variant through the lens of your family’s unique medical journey to guide precise, life‑long eye care.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory Guidance

Post‑test counselling is integral to this genetic test. Our DHA‑licensed genetic counselor will explain results, discuss recurrence risks, and coordinate with your ophthalmologist for ongoing care. Do not make treatment decisions based solely on this report without professional interpretation.

Safety & Exclusion Criteria

Exclusion criteria: Active systemic infection, recent blood transfusion (<4 weeks), or inability to provide informed consent (legal guardian required for minors).
Sample requirements: 2–5 mL whole blood in EDTA, extracted DNA, or one drop of blood on an FTA card. Must be collected under cold‑chain protocol if outside lab.
Emergency red flags: Acute vision loss, severe eye pain, corneal clouding, or sudden eye pressure rise – proceed to the nearest ophthalmology ER immediately. Genetic results will not alter emergent management.
Patient consent: In‑person or digital informed consent required per Federal Decree‑Law No. 4 of 2016 on Medical Liability.

Patient FAQ & Clinical Guidance

1. What does a positive CYP1B1 test mean for my child’s vision?

Snippet Answer: A positive result confirms a pathogenic variant linked to primary congenital glaucoma type 3A, guiding immediate surgical or laser intervention to prevent irreversible optic nerve damage and preserve sight.

The result provides a definitive molecular diagnosis, allowing your paediatric ophthalmologist to tailor treatment and family surveillance with precision. Genetic counselling will explain inheritance risks for future children.

2. How does the home collection service work and is it compliant with UAE data privacy?

Snippet Answer: Our ISO-certified home collection uses encrypted digital consent, a trained phlebotomist with a temperature‑monitored cold chain, and anonymized sample tracking to fully comply with UAE PDPL (Federal Decree‑Law No. 45 of 2021) and Federal Law No. 2 of 2019 concerning health ICT.

Schedule your visit via WhatsApp; we arrive at your doorstep, verify identity, and transport the sample to our DHA‑licensed facility within 2 hours. All genetic data is stored on servers within the UAE with strict access controls.

3. Is this test suitable for newborn screening in the UAE?

Snippet Answer: Yes, the test can be performed on newborns with legal parental consent. A small blood sample (heel prick) or FTA card is used, with results available within 3–4 weeks. It is recommended when congenital glaucoma is clinically suspected or when there is a confirmed family history.

Pre‑ and post‑natal genetic counselling is mandatory for interpretation and family planning.

UAE Regulatory & Data Privacy Adherence

🔬 Regulatory Compliance & Accreditations

Licensed by Dubai Health Authority (DHA) – Facility License No. 1143
Certified to ISO 9001:2015 (Certificate No. INT/EGQ/2509DA/3139)
Data privacy safeguarded under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL); all samples and reports processed solely within UAE borders.
Health information use complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Methodology: Next‑Generation Sequencing (NGS) with Sanger confirmation; LOINC code 82802-1.

Clinical & Logistical Metadata

Test Name	CYP1B1 Gene Glaucoma (Primary Type 3A) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 weeks
Sample Type / Matrix	Peripheral whole blood (EDTA), extracted DNA, or FTA card
Methodology Used	Next‑Generation Sequencing (NGS) confirmed by Sanger sequencing
ICD-10-CM Code	Q15.0, Z13.5, Z84.89
LOINC Code	82802-1
DHA Facility License & Laboratory Address	DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE